Cargando…
Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788807/ https://www.ncbi.nlm.nih.gov/pubmed/35700443 http://dx.doi.org/10.1093/rheumatology/keac326 |
| _version_ | 1784858836179353600 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9788807 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97888072022-12-27 Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus Rheumatology (Oxford) Corrections Oxford University Press 2022-06-14 /pmc/articles/PMC9788807/ /pubmed/35700443 http://dx.doi.org/10.1093/rheumatology/keac326 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Corrections Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus |
| title | Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus |
| title_full | Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus |
| title_fullStr | Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus |
| title_full_unstemmed | Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus |
| title_short | Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus |
| title_sort | correction to: phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus |
| topic | Corrections |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788807/ https://www.ncbi.nlm.nih.gov/pubmed/35700443 http://dx.doi.org/10.1093/rheumatology/keac326 |